Testing a modified immune cell treatment for end-stage enlarged heart muscle
Tests modified immune cells in adults with end-stage enlarged heart muscle.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with dilated cardiomyopathy and severe heart failure that has not improved enough with maximum medicine for at least 3 months.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Dilated cardiomyopathy with heart failure and reduced ejection fraction (HFrEF). Left ventricular ejection fraction below 35%, NYHA class IIIB-IV, INTERMACS class 3-6.
- Earlier treatment
- At least 3 months of optimized drug therapy (GDMT at maximum tolerated dose).
- Biomarker or test result
- Blood test: hematocrit above 30%, lymphocytes above 0.5×10^9/L, platelets above 60×10^9/L.
Main reasons for not taking part
- Heart attack, unstable angina, stroke or mini-stroke in the 12 weeks before enrollment
- Heart failure caused by another heart disease, such as ischemic or hypertrophic cardiomyopathy
- Previous heart transplant or ventricular assist device, or one planned
- Active autoimmune disease needing immunosuppressive treatment
- Hepatitis B, hepatitis C, syphilis or HIV infection, or pregnancy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06902896, who can take part
Where in China
- Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhou, ChinaContact: Xinyang HuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT06902896
- Record updated
- 14 July 2026
- Original description
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.Read full original descriptionShow less
Safety and Efficacy of Immunosuppressive CAR-DC Targeting FAP in the Treatment of End-stage Dilated Cardiomyopathy
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method for the treatment of end-stage dilated cardiomyopathy.
Inclusion: Age between 18 years old and 75 years old, diagnosed with dilated cardiomyopathy; Able to verbally confirm that he/she understands the risks, benefits and treatment options of the iCDC trial. He/she or his/her legal representative provides written informed consent before participating in the clinical trial; Diagnosed with Heart Failure with reduced ejection fraction (HFrEF), optimized drug therapy (under maximum tolerance of GDMT) for at least 3 months, left ventricular ejection fraction <35%, NYHA functional class ⅢB-IV, INTERMACS class 3-6; Blood test: hematocrit >30%, lymphocytes >0.5×10\^9/L, platelets >60×10\^9/L.
Exclusion: History of myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks before enrollment; CRT implanted within 12 weeks before enrollment or intended to implant CRT device; Previous heart transplantation or implantation of a ventricular assist device or similar device, or planned implantation of a ventricular assist device or similar device; History of concurrent severe infection, hepatobiliary obstruction, or malignancy; Contraindications to study drugs or tests; Heart failure caused by ischemic cardiomyopathy, restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, long-standing hypertension, congenital structural heart disease, or uncorrected primary valvular disease; Symptomatic bradycardia or second/third degree heart block; Active autoimmune disease requiring immunosuppressive therapy; A history of tuberculosis; Infections: Active hepatitis B (PCR-detected hepatitis B virus DNA copies > 1000), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection at screening; uncontrolled systemic fungal, bacterial, viral, or other pathogen infection; History of severe renal failure or need for dialysis, creatinine >2.5 mg/dl; Uncorrected thrombocytopenia or systemic coagulopathy (platelet count < 50,000, INR > 2.5, or aPTT > 2.5 times control in the absence of anticoagulation), or active bleeding and uncorrectable coagulopathy; Aspartate aminotransferase or alanine aminotransferase levels greater than 5.0 times the upper limit of normal (ULN), total bilirubin >3 mg/dl; Pulmonary Embolism (PE); Severe hemodynamic instability (eg, shock); Women who are pregnant or may become pregnant.